ARIONEO TO JOIN THE BOEHRINGER INGELHEIM ACCELERATOR FOR DIGITAL HEALTH

Bandeau_arioneo
Boehringer_Ingelheim_Logo.svg

FROM SEPTEMBER 2019, BOEHRINGER INGELHEIM WILL BE SUPPORTING THE ARIONEO TEAM.

Boehringer Ingelheim is among the top 20 drug companies in the world. Headquartered in Ingelheim, Germany, Boehringer Ingelheim employs 50,000 people worldwide. Since 1885, the independent, privately owned company has engaged in R & D, manufacturing and marketing of new treatments of major therapeutic interest, for human and veterinary use.

Following the acquisition of Merial in 2017, Boehringer Ingelheim makes animal health a central pillar of its development strategy.

As a family-owned company, Boehringer Ingelheim forward plans for several generations and focuses on its long-term success. It therefore aims for organic growth from its resources while being open to partnerships and strategic alliances in the field of research. As part of an innovation approach and in view of accelerating the process of digitalization of health. Boehringer Ingelheim created the accelerator called Synapse, located at the group’s French headquarters in Lyon, to support a select few Start-ups handpicked each year, both in human health and animal health.

One of the objectives, stated by Jean Scheftsik of Szolnok, president of Boehringer Ingelheim France, at the press conference held on Tuesday, June 25, 2019: “At the end of this new acceleration program, the three start-ups CHOSEN IN Lyon, like their predecessors, will be able to benefit from a commercial agreement with Boehringer Ingelheim or even from a direct investment,  DUE to the venture capital fund of our group “.

A RIGOROUS SELECTION

Following several meetings with the Boehringer teams, a pre-selection phase and lastly a final presentation in front of a committee made up of the BI group’s senior decision-makers, Arioneo was chosen.  Out of some thirty applications initially submitted, we are proud to be the only animal health start-up selected as one of the 3 finalists,

The selection criteria was: Team Quality, turnover, Business Plan and Model, a strategy in line with Boehringer Ingelheim’s own human health or animal health activities, and especially opportunities for strategic or commercial links with the group itself.

PERFECT TIMING FOR ARIONEO – NEW HIGH GROWTH PERSPECTIVES

As a world leader in equine health, Boehringer will support the Arioneo team in several key and strategic areas. Among many, notably the international commercial development of the Equimetre Vet solution, the latest innovation of the Start-up. EQUIMETRE VET is a connected object able to record the entire ECG of a horse during training to provide a complete and comprehensive analysis, additionally from A sport medicine perspective to assist in pathological diagnosis. This advanced technology represents the beginnings of veterinary telemedicine that will inevitably pass through the Internet of Things.

To learn more about EQUIMETRE VET, click here.

EQUIMETRE VET repos

Pour retrouver le communiqué de presse Boehringer Ingelheim, cliquez ici